Momentum
Previous Close | 2.1700 |
Open | 2.1600 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 2200 |
Day's Range | 2.1600 - 2.2600 |
52 Week Range | 1.1200 - 3.5600 |
Volume | |
Avg. Volume | 38,930 |
Market Cap | 62.808M |
Beta (5Y Monthly) | 0.69 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.2800 |
Earnings Date | Aug 08, 2023 - Aug 14, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
JUPITER, Fla., June 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participa
While not a mind-blowing move, it is good to see that the Dyadic International, Inc. ( NASDAQ:DYAI ) share price has...
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT First Quarter 2023 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) provided 2022 operational and financial results in a press release on May 10, 2023, filed its Form 10-Q with the SEC and held a conference call with investors. Dyadic announced several new collaborations and expanded agreements
New research collaboration with a Top 5 pharmaceutical company to develop C1 expressed vaccine antigen for human healthExpanded licensing agreement with Rubic One Health (“Rubic”) to develop, manufacture and commercialize affordable vaccines and biologics for human and animal health for African ContinentExpanded collaboration with Phibro/Abic animal health to develop vaccines for animal diseasesFully funded co-development and marketing agreement with Fermbox to use Dapibus™ platform to develop a
JUPITER, Fla., May 10, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that they will be participating in the following events during the month of May. PEGS Boston Conf
JUPITER, Fla., May 08, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a co-development and marketing a
JUPITER, Fla., April 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a
JUPITER, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that the company has received a Notice of Allowance from
JUPITER, Fla., April 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced it signed an expanded licensing agreement for its C1-cell
Dyadic International, Inc. (NASDAQ:DYAI) Q4 2022 Earnings Call Transcript March 29, 2023 Operator: Good evening, and welcome to Dyadic International’s Fiscal Year 2022 Financial Results Conference Call. Currently, all participants are in a listen-only mode. Following management’s prepared remarks, there will be a brief question-and-answer session. As a reminder, this conference is being recorded today, […]
Dyadic International ( NASDAQ:DYAI ) Full Year 2022 Results Key Financial Results Revenue: US$2.93m (up 22% from FY...
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) provided 2022 operational and financial results in a press release on March 29, 2023, filed its Form 10-K with the SEC and held a conference call with investors. Dyadic has advanced to the next stage of a development company with C1 derived proteins evaluated in human subjects in the
JUPITER, Fla., March 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccin
Received regulatory approval for the ongoing First-In-Human Phase 1 trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate which has completed dosing of all patients in both the low and high dose testing groupsOngoing research and license agreements with Janssen, Hengrui, NIIMBL and others for the C1-expressed therapeutic proteins for human health Expanded collaboration with Phibro/Abi
JUPITER, Fla., March 15, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it will report its financial results for the year ended 2022 and host a corporate upda
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Dosing of all patients was completed at the end of February No Serious Adverse Events (SAE’s) have been reported Phase 1 clinical initial safety and antibody response update expected in Q2, 2023 JUPITER, Fla., March 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction
JUPITER, Fla., March 01, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its management and business partners from VTT Technical Research Centre of Finland Ltd, wi
JUPITER, Fla., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be participating in the following two upcom
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic International Inc. (NASDAQ:DYAI) achieved a pivotal point in its maturation as a provider of therapeutic proteins as it and partner Rubic One Health dosed its first patient with DYAI-100, a COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate. This is an important milestone as
JUPITER, Fla., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced that, in line with the timing announced during management’s Q3 earnings call, it has initiated dosing in its Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for the DYAI-100 COVID-19 recombinant protein re
JUPITER, Fla., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced that it received approximately $1.27 million in connection with the sale of its equity interest in Alphazyme LL
Dyadic's executive management to attend the J.P. Morgan 41st Annual Healthcare Conference and the 6th Annual BFC Global Healthcare BD and Investment Conference from January 8-12 in San Francisco, CA USAJUPITER, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effect
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s anticipated First-In-Human clinical trial designed to demonstrate clinical safety and immune response in humans for its DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidate.The C1-cell produced RBD-C-tag antigen strongly binds ACE2 receptors in vitro. Adjuvanted RBD-C-tag-based vaccine ca
By John Vandermosten, CFA NASDAQ:DYAI READ THE FULL DYAI RESEARCH REPORT Third Quarter 2022 Operational & Financial Results Dyadic International Inc. (NASDAQ:DYAI) provided third quarter 2022 operational and financial results in a press release on November 10, 2022, filed its Form 10-Q with the SEC and hosted a conference call with investors. Dyadic is more explicitly orienting its efforts